B2BinPay v20 Increases Functionality with TRX Staking and Broader Blockchain Support
6.6.2024 11:31:00 EEST | Business Wire | Press release
The industry-leading blockchain platform, B2BinPay, has improved even further. The most recent version offers clients more flexibility and efficiency by expanding blockchain functionality and introducing TRX staking. Let's review how these new features improve B2BinPay's user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606092849/en/
B2BinPay version 20 arrives with TRX staking feature and expanded blockchain support (Graphic: Business Wire)
TRX Staking – Earn While You Transact!
The launch of TRX Staking, based on the advanced Stake 2.0 mechanism developed by the TRON community, is a crucial highlight of B2BinPay v20. With its increased flexibility, simplified user interface, and improved resource delegation and utilisation efficiency, this new approach surpasses the previous Stake 1.0.
TRX staking empowers B2BinPay clients to stake any amount of TRX and earn a passive annual yield of 3-5% (subject to network conditions). But this is not all. By staking TRX, users can significantly reduce transaction fees on the TRON network. Staked TRX is converted into bandwidth and energy, two necessary resources, to achieve this.
Smart contracts run on energy, and transaction processing capability is provided by bandwidth. By staking TRX and acquiring these resources, companies and individuals can increase transaction efficiency and save operating costs, providing them a distinct competitive advantage.
Getting started with TRX Staking on B2BinPay is straightforward:
➔ Begin by converting your TRX into either Bandwidth or Energy based on the specific processing needs of your chosen asset type.
➔ After that, delegate your votes converted from Bandwidth or Energy to SR.
New Blockchains Supported
Building on the previous integration of Polygon and Avalanche, the addition of Optimism, Arbitrum, and Base—all of which provide native support for stablecoins—significantly broadens B2BinPay v20's support for blockchain technology.
Optimism
Optimism is a Layer 2 solution that scales the Ethereum leading network by batching transactions. It collects transaction data from the Ethereum blockchain, processes it in batches, and sends it back to the Ethereum mainnet for validation. Since its launch in 2021, Optimism has reduced fees by ten times compared to Ethereum's base level. Users have saved over $1 billion in gas payments, making it one of the most cost-effective blockchains.
Arbitrum
Arbitrum is an Ethereum scaling solution that increases transaction volumes while lowering costs. It shares Ethereum's tooling, enabling developers to deploy DApps on Arbitrum quickly and securely. This compatibility extends to stablecoins, offering users more choices.
Base
Base, developed by Coinbase, optimises Optimism’s OP Stack for enhanced EVM compatibility. This open-source rollup supports stablecoins and makes code deployment easier on Ethereum and compatible blockchains.
Why Does Expanded Blockchain Support Matter for Clients?
By incorporating additional blockchains, B2BinPay expands the range of transaction options, aligning with your business requirements using suitable technology. Specifically, B2BinPay now supports:
USDT on 7 networks:Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, and Arbitrum.
USDC on 8 networks: Ethereum, Binance Smart Chain, Tron, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Bridged USDC on 4 networks: Avalanche, Polygon, Optimism, and Arbitrum.
Here are other use cases of how the blockchain expansion can benefit you.
Streamlining Withdrawals for End-Users
Suppose your end-user needs to withdraw funds in a currency that's not immediately available. In that case, B2BinPay allows for swift asset conversion to meet currency requirements and handle associated transaction fees, ensuring the timely fulfilment of withdrawal requests.
Reducing Blockchain Transaction Fees
If you aim to lower the cost of USDT transactions, B2BinPay offers an effective solution by allowing you to aggregate USDT from various blockchains, such as Ethereum or Optimism, into a single swap wallet.
Ensuring Liquidity for Trading Platforms
Suppose you have significant cryptocurrency funds and urgent requirements like stopouts on trading platforms. In that case, you can rely on B2BinPay's extensive blockchain support to quickly convert assets into the required currency for deposit. This feature assists you in maintaining liquidity and enables quick responsiveness to market demands.
Final Remarks
According to the official statements, Algorand and Solana will be introduced in the upcoming release. With this expansion, there will be 10 blockchains that enable stablecoin transactions, including those already used: Ethereum, Tron, Binance Smart Chain, Avalanche, Polygon, Optimism, Arbitrum, and Base.
Connect with B2BinPay and unlock your business potential with advanced blockchain payment processing solutions!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606092849/en/
Contact information
sales@b2binpay.com
+357 250-308-82
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom